Yahoo Movies
Don't knock the Lightning for Nikita Kucherov situation
The Tampa Bay Lightning had a star player that needed surgery. In the NHL's highly limiting financial world, they shouldn't be crushed for choosing the most beneficial time for that procedure.
The Tampa Bay Lightning had a star player that needed surgery. In the NHL's highly limiting financial world, they shouldn't be crushed for choosing the most beneficial time for that procedure.
The FBI tapped an Australian company to help it unlock the San Bernardino shooter's iPhone 5C.
WASHINGTON — President Joe Biden says the Sept. 11 attacks “cannot explain” why U.S. forces should remain in Afghanistan 20 years later and that “it is time for American troops to come home” from the country's longest war. Biden, in excerpts of a speech to the nation he plans later Wednesday, says the U.S. cannot continue to pour resources into an intractable war and expect different results. The White House released the excerpts before the afternoon address when he plans to detail his timeline for a U.S. troop withdrawal. “We cannot continue the cycle of extending or expanding our military presence in Afghanistan hoping to create the ideal conditions for our withdrawal, expecting a different result,” Biden says. “I am now the fourth American president to preside over an American troop presence in Afghanistan. Two Republicans. Two Democrats. I will not pass this responsibility to a fifth.” Biden says he consulted with allies, military leaders, lawmakers and Vice-President Kamala Harris to help make his decision to withdraw all U.S. troops by Sept. 11, two decades after the deadliest attack on American soil. He is emphasizing that his administration will continue to support peace talks between the Afghan government and the Taliban and assist international efforts to train the Afghan military. “It is time to end America’s longest war,” Biden says. “It is time for American troops to come home.” THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. President Joe Biden will withdraw all U.S. troops from Afghanistan by Sept. 11, the 20th anniversary of the terrorist attacks on America that were co-ordinated from that country, several U.S. officials said. Biden will lay out his vision for the way forward in Afghanistan and the timeline for the withdrawal in remarks Wednesday afternoon, The White House said. Punctuating the nearly two decades U.S. troops have fought and died in Afghanistan, the president will then visit Section 60 of Arlington National Cemetery to honour the sacrifice of those who died in recent American conflicts. The decision to withdraw troops by fall defies a May 1 deadline for full withdrawal under a peace agreement the Trump administration reached with the Taliban last year, but leaves no room for additional extensions. A senior administration official on Tuesday called the September date an absolute deadline that won't be affected by security conditions in the country. While Biden's decision keeps U.S. troops in Afghanistan four months longer than initially planned, it sets a firm end to two decades of war that killed more than 2,200 U.S. troops, wounded 20,000, and cost as much as $1 trillion. The conflict largely crippled al-Qaida and led to the death of Osama bin Laden, the architect of the Sept. 11 attacks. But an American withdrawal also risks many of the gains made in democracy, women's rights and governance, while ensuring that the Taliban, who provided al-Qaida's haven, remain strong and in control of large swaths of the country. Biden has been hinting for weeks that he was going to let the May deadline lapse, and as the days went by it became clear that an orderly withdrawal of the roughly 2,500 remaining troops would be difficult and was unlikely. The administration official said the drawdown would begin by May 1. Biden's choice of the 9-11 date underscores the reason that American troops were in Afghanistan to begin with — to prevent extremist groups like al-Qaida from establishing a foothold again that could be used to launch attacks against the U.S. The administration official said Biden decided that the withdrawal deadline had to be absolute, rather than based on conditions on the ground. “We’re committing today to going to zero” U.S. forces by Sept. 11, and possibly well before, the official said, adding that Biden concluded that a conditioned withdrawal would be “a recipe for staying in Afghanistan forever.” Defence officials and commanders had argued against the May 1 deadline, saying the U.S. troop withdrawal should be based on security conditions in Afghanistan, including Taliban attacks and violence. White House press secretary Jen Psaki didn't provide details of Biden's remarks planned for Wednesday, but she said during a White House briefing that Biden "has been consistent in his view that there is not a military solution to Afghanistan, that we have been there for far too long.” Psaki tweeted later Tuesday that Biden's visit to Arlington National Cemetery was “to pay his respects to the brave men and women who have paid the ultimate sacrifice in Afghanistan.” Several U.S. officials confirmed Biden’s withdrawal decision to The Associated Press, and an administration official provided details to reporters on condition of anonymity, speaking ahead of the announcement. According to the administration official, the only U.S. forces remaining in Afghanistan will be those needed to protect diplomats there. No exact number was provided, but American troop totals in Afghanistan have been understated by U.S. administrations for years. Officials have quietly acknowledged that there are hundreds more in Afghanistan than the official 2,500 number, and likely would include special operations forces conducting covert or counterterrorism missions, often working with intelligence agency personnel. Biden's new, extended timeline will allow a safe and orderly withdrawal of American troops in co-ordination with NATO allies, the administration official added. The president's decision, however, risks retaliation by the Taliban on U.S. and Afghan forces, possibly escalating the 20-year war. And it will reignite political division over America’s involvement in what many have called the endless war. An intelligence community report issued Tuesday about global challenges for the next year said prospects for a peace deal in Afghanistan are “low” and warned that “the Taliban is likely to make gains on the battlefield. If the coalition withdraws support, the report says, the Afghan government will struggle to control the Taliban. Congressional reaction to the new deadline was mixed. “Precipitously withdrawing U.S. forces from Afghanistan is a grave mistake," said Senate Republican leader Mitch McConnell, R-Ky. “It is retreat in the face of an enemy that has not yet been vanquished and abdication of American leadership.” Sen. Jim Inhofe of Oklahoma, the ranking Republican on the Senate Armed Services Committee, slammed it as a “reckless and dangerous decision.” He said any withdrawal should be conditions-based, adding that arbitrary deadlines could put troops in danger, create a breeding ground for terrorists and lead to civil war in Afghanistan. Democrats were generally more supportive. Sen. Jack Reed, D-R.I., chairman of the Armed Services Committee, said President Donald Trump’s May 1 deadline limited Biden’s options. “We still have vital interests in protecting against terrorist attacks that could be emanating from that part of the world, but there are other areas, too, we have to be conscious of,” Reed said. Sen. Tim Kaine, D-Va., said troops should come home, and the U.S. must refocus American national security on more pressing challenges. But at least one senior Democrat expressed disappointment. Sen. Jeanne Shaheen of New Hampshire said in a tweet that the U.S. “has sacrificed too much to bring stability to Afghanistan to leave w/o verifiable assurances of a secure future.” Taliban spokesman Zabihullah Mujahed told the AP that the religious militia is waiting for a formal announcement to issue its reaction. The Taliban previously warned the U.S. of “consequences” if it reneged on the May 1 deadline. In a February 2020 agreement with the Trump administration, the Taliban agreed to halt attacks and hold peace talks with the Afghan government, in exchange for a U.S. commitment to a complete withdrawal by May 2021. Over the past year, U.S. military commanders and defence officials have said that attacks on U.S. troops have largely paused, but that Taliban attacks on the Afghans increased. Commanders have argued that the Taliban have failed to meet the conditions of the peace agreement by continuing attacks on the Afghans and failing to totally cut ties with al-Qaida and other extremist groups. When Biden entered the White House in January, he was keenly aware of the looming deadline and had time to meet it if he had chosen to do so. He began a review of the February 2020 agreement shortly after taking office, and has been consulting at length with his defence advisers and allies. In recent weeks, it became increasingly clear that he was leaning toward defying the deadline. “It’s going to be hard to meet the May 1 deadline,” Biden said in March. “Just in terms of tactical reasons, it’s hard to get those troops out.” He added, “And if we leave, we’re going to do so in a safe and orderly way.” ___ Knickmeyer reported from Oklahoma City. Associated Press writers Kathy Gannon in Islamabad and Eric Tucker in Washington and broadcast correspondent Sagar Meghani contributed to this report. Lolita C. Baldor And Ellen Knickmeyer, The Associated Press
Global banking rulemakers need to undertake further analysis to clarify if lenders need to build up bigger capital buffers to cover possible environmental risks, the Swiss-based Basel Committee of banking regulators said on Wednesday. Central banks and investors are piling pressure on lenders to quantify the impact of climate-related risks from floods and fires on the stocks, bonds, property and loans to companies they hold on their balance sheets. The Basel Committee of regulators from more than 20 countries writes rules for banks to quantify different types of risks, such as from loans and other activities.
AM Best has revised the outlooks to stable from negative and affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of "bbb-" of Tugu Insurance Company Limited (TIC) (Hong Kong).
Senator Chris Murphy (D-CT) joins Michael Isikoff, Daniel Klaidman and Victoria Bassetti on this episode to talk about his renewed push for gun control legislation now, in the wake of recent shootings in Atlanta and Boulder.
GenTrust, a growing investment advisory firm with offices in Miami, New York and Puerto Rico, announced today that Mimi Duff has joined the firm’s Wealth Advisor team out of its New York office.
14 April, 2021, 16:15 CET ArcelorMittal Italia to be renamed Acciaierie d’Italia ArcelorMittal announces that it has today completed an investment agreement (the ‘Investment Agreement’) with Invitalia, an Italian state-owned company, forming a public-private partnership between the parties. Invitalia has injected €400 million new equity into AM InvestCo Italy, ArcelorMittal’s subsidiary which signed the lease and purchase agreement for the Ilva business, providing Invitalia with a 38% shareholding and equal voting rights with joint control over the company. Going forward the joint company AM InvestCo Italy is being re-named Acciaierie d’Italia Holding, and its main operating subsidiary ArcelorMittal Italia will be renamed Acciaierie d’Italia. The Investment Agreement stipulates a second equity injection by Invitalia, of up to €680 million, to fund the completion of the purchase of Ilva’s business by Acciaierie d’Italia, which is expected by May 2022 subject to certain conditions precedent*. At this point, Invitalia’s shareholding in Acciaierie d’Italia would increase to 60%, with ArcelorMittal to invest up to €70 million to retain a 40% shareholding and joint control over the company. Going forward, Acciaierie d’Italia Holding will operate independently, and as such will have its own funding plans without reliance on ArcelorMittal. As a result, ArcelorMittal will deconsolidate the assets and liabilities (including the remaining lease and purchase liability) of Acciaierie d’Italia Holding (formerly AM InvestCo Italy) from its consolidated statement of financial position and will account its interest in the company under the equity method. *The conditions precedent include: the amendment of the existing environmental plan to account for changes in the new industrial plan; the lifting of all criminal seizures on the Taranto plant; and the absence of restrictive measures – in the context of criminal proceedings where Ilva is a defendant – being imposed against Acciaierie d’Italia Holding or its subsidiaries. In case conditions precedent are not met, then the Acciaierie d’Italia Holding would not be required to complete the purchase of Ilva’s assets and its capital invested would be returned.
Redding, California, April 14, 2021 (GLOBE NEWSWIRE) -- According to a new market research report titled “Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2027”, published by Meticulous Research®, the continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach $197.8 million by 2027. Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5079 Continuous bioprocessing consists of integrated continuous unit processes without intermediate holding tanks through which product travels into containers in a constant flow. Continuous unit operations are characterized by extremely intensified processing with short downtimes. An end-to-end bioprocess includes perfusion bioreactors, multi-column chromatography systems, and multi-column intermediate purification systems. Some pharma and biopharma manufacturers are adopting a hybrid approach to continuous bioprocessing in which only upstream or downstream process is operated continuously. The growth in the continuous bioprocessing market is mainly attributed to the growing demand for biopharmaceuticals, growing development of new technologies and products related to continuous bioprocessing, and rising government support for biopharmaceutical manufacturing. In addition, significant opportunities in Asia-Pacific and Latin America and growing approval for personalized medicines further support this market's growth. However, factors such as the high risk of contamination with continuous bioprocessing, the complex nature of continuous bioprocessing in downstream processes, and the shortage of bioprocessing professionals are expected to hinder the adoption of continuous bioprocessing. Over the years, several advances have been made in bioprocessing to cut costs, improve product yield, and streamline integration between upstream and downstream processing. Advances in upstream processing have focused on key areas like increased volumetric productivity through process intensification, increasing cell-specific productivity, greater cellular and molecular biology, and accelerating process development timeline. Bioprocessing operations have also led to other innovations like continuous improvements in cell expression systems and development and improvement of disposable bioreactors impacting bioprocessing operations, leading to new product launches. For instance, in September 2020, Cytiva (U.S.) launched its Xcellerex Automated Perfusion System (APS) for biotherapeutic manufacturing. Impact of COVID-19 on the Continuous Bioprocessing Market The global COVID-19 pandemic has affected the healthcare industry diversely. The adoption of continuous bioprocessing technologies is expected to rise due to accelerated R&D to manufacture COVID-19 vaccines. To curb the spread of the novel COVID-19 virus, countries worldwide went under strict lockdowns, which resulted in the disrupted supply chains for sourcing raw materials. With the growing vaccine and therapeutic candidates in the pipeline, the demand for novel manufacturing approaches like continuous processing is accelerating, positively impacting the market. Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5079 The biopharma industry is focusing on adopting flexible and adaptable approaches, necessitating the adoption of flexible manufacturing strategies like continuous bioprocessing. This adaptability helps the industry develop and produce COVID-19 vaccines, diagnostics, equipment, and therapeutics. Attention has focused on the development of vaccines, new antiviral agents, and convalescent plasma infusions. For instance, monoclonal antibodies, a type of therapeutic agent, are under investigation to treat COVID-19. In November 2020, the FDA granted emergency use authorization for both bamlanivimab and the combination of casirivimab and imdevimab in outpatients with mild to moderate COVID-19 who are at high risk for severe COVID-19. The companies like GlaxoSmithKline Plc. (U.K.), Sanofi (France), Johnson & Johnson (U.S.) are exploring different approaches like recombinant protein therapy and viral vector platforms for discovering COVID-19 vaccine modalities. The continuous bioprocessing market is segmented on the basis of product (filtration, chromatography, centrifuges, consumables), application (commercial {vaccines, monoclonal antibodies}, R&D), end user (pharmaceuticals, biotechnology, CROs), and geography. The study also evaluates industry competitors and analyzes their market share at the global and regional levels. Based on product, the filtration systems and consumables segment accounted for the largest share of the overall continuous bioprocessing market in 2020. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for this segment's growth. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion. Quick Buy – Continuous Bioprocessing Market Research Report: https://www.meticulousresearch.com/Checkout/13717155 On the basis of application, the commercial segment accounted for the largest share of the overall continuous bioprocessing market in 2020. Growing investments in constructing facilities compatible with continuous bioprocessing for biopharmaceuticals' commercial manufacturing is a key market driver. Also, the growing approval of antibodies and therapeutic proteins and on-going and future capacity expansions by various commercial biopharmaceutical manufacturers to cater to unmet demand for vaccines and other biopharmaceutical products in a short period is accelerating the growth of this segment. Commercial manufacturing includes vaccine manufacturing, mAb manufacturing, gene and cell therapy manufacturing, and recombinant protein production. In 2020, the mAb manufacturing segment accounted for the largest share of the market. Based on end user, CDMOs and CROs segment is projected to grow at the highest CAGR over the forecast period due to the growing trend towards outsourcing biologics manufacturing and favorable regulatory reforms for CMOs. Some of the key players operating in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (The Netherlands), Pall Corporation (U.S.), and Bionet (Spain) among others. To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/continuous-bioprocessing-market-5079 Scope of the Report: Continuous Bioprocessing Market, by Product Filtration Systems and ConsumablesChromatography Systems and ConsumablesBioreactorsSterilizersCentrifugesIncubators and ShakersMixing SystemsCell Culture Media, Buffers, and ReagentsOther Instruments and Consumables Continuous Bioprocessing Market, by Application Commercial VaccinesmAb ProductionRecombinant Protein ProductionCell and Gene Therapy Production R&D Continuous Bioprocessing Market, by End User Pharmaceutical and Biotechnology CompaniesContract Development and Manufacturing Organizations and Contract Research OrganizationsAcademic and Research Institutes Continuous Bioprocessing Market, by Geography North America U.S.Canada Europe GermanyU.K.France ItalySpainRest of Europe (RoE) Asia-Pacific (APAC) ChinaJapanIndiaRest of APAC (RoAPAC) Latin AmericaMiddle East & Africa Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5079 Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here- https://www.meticulousresearch.com/custom-research Related Reports: Biopharmaceutical Processing Equipment and Consumables Market by Product (Filtration, Chromatography, Columns, Bioreactor, Cell Culture, Service), Application (Commercial, Research), And End User (Pharmaceutical, Biotechnology, CDMO)- Global Forecast To 2023https://www.meticulousresearch.com/product/biopharmaceutical-processing-equipment-consumables-market-4200 Cell Culture Market by Product [Consumables (Media, Reagents, Sera, FBS, Antibiotics, Growth Factor, Buffer), Equipment (Bioreactor, Centrifuge)], Application (Biopharmaceutical, Cancer, Stem Cell), and End User (Pharma, Research)- Global Forecast to 2024https://www.meticulousresearch.com/product/cell-culture-market-4788 Downstream Bio-processing Controllers Market by Procedure (Chromatography, TFF), Product (Chromatography Controller System, TFF Controller System, Disposable Flow Path], Application (Commercial, Research), and End User - Global Forecasts to 2025 https://www.meticulousresearch.com/product/downstream-bio-processing-controllers-market-5033 Contract Research Organizations (CRO) Market by Services (Clinical Research [Phase II, Phase III], Pre-Clinical [Pharmacokinetics, Toxicology], Laboratory Services, and others), Therapeutic Area (Oncology, Immunology), End User (Pharma and Biotech, Medical Device), and Geography - Forecast to 2027 https://www.meticulousresearch.com/product/CRO-market-5129 About Meticulous Research® Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact:Mr. Khushal BombeMeticulous Market Research Inc.1267 Willis St, Ste 200 Redding, California, 96001, U.S.USA: +1-646-781-8004Europe : +44-203-868-8738APAC: +91 744-7780008Email- sales@meticulousresearch.com Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/266/continuous-bioprocessing-market-2027 CONTACT: Mr. Khushal Bombe Meticulous Research® Direct Lines: +1-646-781-8004 (North America) Email- sales@meticulousresearch.com Visit Our Website: https://www.meticulousresearch.com/
Ranger Energy Services, Inc. (NYSE: RNGR) ("Ranger" or the "Company") announced today it has completed a sale-leaseback real estate transaction related to one of its operations facilities, delivering $13 million in gross proceeds.
Prince Philip's funeral limited to 30 people. Johnson & Johnson vaccine gets reviewed. US warns of global pandemic 'aftershocks'. Latest COVID news.
The development has been adjusted to preserve the ancient complex, which included a circular room with several more leading off it and a bathhouse.
Experts share advice on making a plan and keeping yourself motivated
The film highlights an ‘important public health issue’, Downing Street said.
MONTREAL — Cogeco Inc. says its second-quarter net profit was $110.2 million, down from a year ago, as higher financial and income tax expenses offset revenue gains at its main subsidiary. The Montreal-based company, which successfully fended off a hostile takeover attempt by Rogers Communications Inc. last year, says its net profit for the three months ended Feb. 28 was equal to $2.11 per diluted share of Cogeco Inc. The result compared with a net profit of $113.4 million or $2.18 per diluted share of Cogeco Inc. in the second quarter of the company's 2020 financial year. Cogeco Inc.'s revenue rose to $653.2 million from $610.8 million a year ago, most of it generated by its publicly traded telecommunications subsidiary. Cogeco Communications Inc. reported separately revenue of $634.5 million for the three months ended Feb. 28, up from $586.5 million a year earlier. The cable and internet subsidiary, which operates in Quebec, Ontario and the United States, earned $110.6 million or $2.14 per Cogeco Communications share, down from $114.0 million or $2.22 per share a year earlier. Revenue at Cogeco Communications was up mainly because of a friendly takeover of Quebec-based DERYTelecom, which closed in December. This report by The Canadian Press was first published April 14, 2021. Companies in this story: (TSX:CGO, TSX:CGA) The Canadian Press
The star tells BBC 6 Music about working with Dave Grohl and the true story behind his lost memoirs.
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Heavy-duty trucks Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- The Global Heavy-Duty Trucks Market is expected to grow at a CAGR of around 4.3% from 2020 to 2027 and reach the market value of over US$ 549.8 Bn by 2027. The heavy-duty trucks market is segmented on the basis of propulsion type, application type, tonnage type, and geography. By propulsion type, market segments include IC engine, hybrid, and electric. The heavy-duty trucks have applications across freight & logistics, construction & mining, and other applications. Based on tonnage type, the market is bifurcated into 10–15 metric tons, and over 15 metric tons. In 2019, the IC Engine segment on the basis of propulsion type accounted for the maximum revenue share (%). The heavy-duty trucks propelled by the diesel engine registered the maximum share and work efficiency. The cost efficiency and easy availability associated with diesel is supporting the segmental market value. Whereas, the increasing focus towards the environment-friendly solution for transportation is projected to hinder the growth of diesel vehicles over the forecast period. DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2566 Additionally, the increasing production and development of electric trucks are projected to exhibit the fastest growth with a major CAGR (%) throughout the forecast timeframe from 2020 to 2027. The increasing focus towards electric vehicles to decrease the carbon footprints is supporting the segmental market value. Asia Pacific is expected to hold the major share (%) in terms of revenue (US$ Mn) of the global heavy-duty trucks market. The region is gaining pace on account of its developing economies including China and India. The increasing production of commercial vehicles in the region due to expanding industrial sector along with the increasing import and export activities is propelling the regional market value. The presence of manufacturing plants of major global players in the region is additionally accelerating the regional market value. The rapid industrialization along with the increasing demand for industrial products in the region is bolstering the market growth. VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/heavy-duty-trucks-market Some of the leading competitors are Ashok Leyland (India), China National Heavy Duty Truck Group, Daimler AG (Germany), Dongfeng Motor Corporation (China), FAW Group Corporation (China), Freightliner Trucks (US), Isuzu Motors Ltd (Japan), Kenworth Truck Company (US), PACCAR (US), Tata Motors Limited (India), Traton AG (Germany), and Volvo Trucks (Sweden). Heavy-duty truck companies have announced strategic mergers and acquisitions, partnerships & collaboration, and new product development to expand their position in the heavy-duty trucks industry. Major players are also moving into new regions with advanced technologies for gaining a competitive advantage. Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Some of the key observations regarding the heavy-duty trucks industry include: Voorhoeve, Volvo President has mentioned the plans of scaling the production of the vehicles at a company factory in Virginia by the end of 2020. Volvo has rolled out a fleet of 70 electric trucks in 2020 the company has a handful of battery-electric Volvo VNR heavy-duty trucks operated by its customers. The environmental agencies of California support the program with financial incentives and other funding.In August 2020, Utility Minnesota Power is planning to help mining companies to convert to electric mining vehicles. For the same, Minnesota Power has proposed a pilot project to state regulators, the project would help the region’s iron and taconite mines by acquiring heavy-duty electric vehicles to help in reducing the carbon footprint.Xos, a startup building electric vehicles is developing a Class 8 heavy-duty truck, ET-One. The ET-One would be production-ready by the end of 2020. The startup has recently announced a partnership with automotive supplier Metalsa in 2020. It has also announced the funding of US$ 20 million backed by a group of investors that includes Proeza Ventures.Daimler AG has experienced the increased demand of 14,000 trucks in 2020 from the last year, particularly from the construction, mining, and e-commerce sectors. The company has added a second shift from august 2020 at its factory near the southern Indian city of Chennai. The factory outlet has a capacity of making 72,000 trucks and 4,000 buses a year. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2566 BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2566 Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting
The Commons Defence Committee chairman said it would also make it ‘very difficult’ for British armed forces to remain in the Asian country.
Sweden's Health Agency said on Wednesday it would pause plans to start vaccinations using Johnson & Johnson's COVID-19 vaccine following reports of rare blood clots similar to those reported for the AstraZeneca shot. The Health Agency said in a statement it would not start the vaccinations and await the findings of a review by the European Medicines Agency (EMA). The vaccine has not yet been used in Sweden though a first batch of 31,000 doses has arrived in the country.
‘I think we are going to be hearing about a decision pretty quickly,’ Dr Fauci says about the vaccine pause
U.S. Treasury yields rose on Wednesday as several Federal Reserve officials, including Chair Jerome Powell, were set to speak in the wake of the latest inflation data. The benchmark 10-year yield was last up 1.5 basis points at 1.6376%. "It's more likely yields drift higher from here, and the reason is we're just getting a lot of positive global economic data," said Kathy Jones, chief fixed income strategist at the Schwab Center for Financial Research in New York.